242 related articles for article (PubMed ID: 23622183)
21. Tuberous sclerosis complex.
Hasbani DM; Crino PB
Handb Clin Neurol; 2018; 148():813-822. PubMed ID: 29478616
[TBL] [Abstract][Full Text] [Related]
22. The Evolving Landscape of Therapeutics for Epilepsy in Tuberous Sclerosis Complex.
Vitale G; Terrone G; Vitale S; Vitulli F; Aiello S; Bravaccio C; Pisano S; Bove I; Rizzo F; Seetahal-Maraj P; Wiese T
Biomedicines; 2023 Dec; 11(12):. PubMed ID: 38137462
[TBL] [Abstract][Full Text] [Related]
23. Cardiac rhabdomyomas in tuberous sclerosis complex show apoptosis regulation and mTOR pathway abnormalities.
Kotulska K; Larysz-Brysz M; Grajkowska W; Jóźwiak J; Włodarski P; Sahin M; Lewin-Kowalik J; Domańska-Pakieła D; Jóźwiak S
Pediatr Dev Pathol; 2009; 12(2):89-95. PubMed ID: 17990907
[TBL] [Abstract][Full Text] [Related]
24. Brain Symptoms of Tuberous Sclerosis Complex: Pathogenesis and Treatment.
Mizuguchi M; Ohsawa M; Kashii H; Sato A
Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34206526
[TBL] [Abstract][Full Text] [Related]
25. Updated Genotype-Phenotype Correlations in TSC.
Curatolo P; Trivisano M; Specchio N
Semin Pediatr Neurol; 2023 Oct; 47():101086. PubMed ID: 37919037
[TBL] [Abstract][Full Text] [Related]
26. [Autism, epilepsy and tuberous sclerosis complex: a functional model linked to mTOR pathway].
García-Peñas JJ; Carreras-Sááez I
Rev Neurol; 2013 Feb; 56 Suppl 1():S153-61. PubMed ID: 23446718
[TBL] [Abstract][Full Text] [Related]
27. Rapamycin as a therapy of choice after renal transplantation in a patient with tuberous sclerosis complex.
Tarasewicz A; Debska-Slizień A; Konopa J; Zdrojewski Z; Rutkowski B
Transplant Proc; 2009 Nov; 41(9):3677-82. PubMed ID: 19917366
[TBL] [Abstract][Full Text] [Related]
28. Emerging treatments in the management of tuberous sclerosis complex.
Kohrman MH
Pediatr Neurol; 2012 May; 46(5):267-75. PubMed ID: 22520346
[TBL] [Abstract][Full Text] [Related]
29. Loss of expression of tuberin and hamartin in tuberous sclerosis complex-associated but not in sporadic angiofibromas.
Fackler I; DeClue JE; Rust H; Vu PA; Kutzner H; Rütten A; Kaddu S; Sander CA; Volkenandt M; Johnson MW; Vinters HV; Wienecke R
J Cutan Pathol; 2003 Mar; 30(3):174-7. PubMed ID: 12641776
[TBL] [Abstract][Full Text] [Related]
30. Localization of tuberous sclerosis 2 mRNA and its protein product tuberin in normal human brain and in cerebral lesions of patients with tuberous sclerosis.
Kerfoot C; Wienecke R; Menchine M; Emelin J; Maize JC; Welsh CT; Norman MG; DeClue JE; Vinters HV
Brain Pathol; 1996 Oct; 6(4):367-75. PubMed ID: 8944308
[TBL] [Abstract][Full Text] [Related]
31. Tuberous sclerosis complex: a review of the management of epilepsy with emphasis on surgical aspects.
Connolly MB; Hendson G; Steinbok P
Childs Nerv Syst; 2006 Aug; 22(8):896-908. PubMed ID: 16770618
[TBL] [Abstract][Full Text] [Related]
32. Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling.
Tee AR; Fingar DC; Manning BD; Kwiatkowski DJ; Cantley LC; Blenis J
Proc Natl Acad Sci U S A; 2002 Oct; 99(21):13571-6. PubMed ID: 12271141
[TBL] [Abstract][Full Text] [Related]
33. Is tuberous sclerosis complex-associated autism a preventable and treatable disorder?
Curatolo P; Scheper M; Emberti Gialloreti L; Specchio N; Aronica E
World J Pediatr; 2024 Jan; 20(1):40-53. PubMed ID: 37878130
[TBL] [Abstract][Full Text] [Related]
34. Developmental expression of the tuberous sclerosis proteins tuberin and hamartin.
Murthy V; Stemmer-Rachamimov AO; Haddad LA; Roy JE; Cutone AN; Beauchamp RL; Smith N; Louis DN; Ramesh V
Acta Neuropathol; 2001 Mar; 101(3):202-10. PubMed ID: 11307618
[TBL] [Abstract][Full Text] [Related]
35. Mechanistic target of rapamycin (mTOR) in tuberous sclerosis complex-associated epilepsy.
Curatolo P
Pediatr Neurol; 2015 Mar; 52(3):281-9. PubMed ID: 25591831
[TBL] [Abstract][Full Text] [Related]
36. The tuberous sclerosis complex genes in tumor development.
Mak BC; Yeung RS
Cancer Invest; 2004; 22(4):588-603. PubMed ID: 15565817
[TBL] [Abstract][Full Text] [Related]
37. Mammalian target of rapamycin inhibitors for treatment in tuberous sclerosis.
Kim WS
Korean J Pediatr; 2011 Jun; 54(6):241-5. PubMed ID: 21949518
[TBL] [Abstract][Full Text] [Related]
38. Differentiating the mTOR inhibitors everolimus and sirolimus in the treatment of tuberous sclerosis complex.
MacKeigan JP; Krueger DA
Neuro Oncol; 2015 Dec; 17(12):1550-9. PubMed ID: 26289591
[TBL] [Abstract][Full Text] [Related]
39. Evidence for separable functions of tuberous sclerosis gene products in mammalian cell cycle regulation.
Miloloza A; Kubista M; Rosner M; Hengstschläger M
J Neuropathol Exp Neurol; 2002 Feb; 61(2):154-63. PubMed ID: 11853018
[TBL] [Abstract][Full Text] [Related]
40. Genotype/Phenotype Correlations in Tuberous Sclerosis Complex.
Curatolo P; Moavero R; Roberto D; Graziola F
Semin Pediatr Neurol; 2015 Dec; 22(4):259-73. PubMed ID: 26706013
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
